This online CME program - presented during the 6th European Congress of Endocrinology (EFES) in Lyons, France on April 26, 2003, at the Serono Symposia International Satelitte Symposium – reviewed the results of a clinical study that evaluated the effects and safety of r-hGH replacement therapy in Adult Growth Hormone Deficiency (AGHD). The results of a short-term double-blind placebo controlled phase of 6 months were provided together with a long-term open-label phase up to 30 months and confirmed the sustained benefits and safety of r-hGH replacement therapy in AGHD.


Learning Objectives

Upon completion of this program, the participant will be able to:

• Identify the results of a clinical study that evaluates the effects of r-hGH replacement therapy in AGHD.
• Understand the short and long-term clinical benefits of r-hGH replacement therapy on body composition and cardiac function in AGHD.
• Discuss the safety aspects of r-hGH replacement therapy in AGHD.